Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
249 participants
OBSERVATIONAL
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
NCT02061670
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
NCT02061709
Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma
NCT02161107
ToleroMune Ragweed Follow up Study
NCT01448603
Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis
NCT00878774
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TR006 Subjects
Subjects that have previously been randomised into study TR006
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with significant allergy to animal dander
* Any allergen immunotherapy since completing Study TR006 or use of prohibited therapies
* History of recurrent acute sinusitis or chronic sinusitis
* Received treatment with an investigational drug within 4 weeks of Screening
* Unable to understand study requirements or unable to communicate clearly with Investigator
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adiga Life Sciences, Inc.
INDUSTRY
Circassia Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kanata Allergy Services
Kanata, Ontario, Canada
Inflamax Research
Mississauga, Ontario, Canada
Windsor Allergy Asthma Associates
Windsor, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TR006A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.